Clinical studies have shown promising results in patients with metastatic triple negative breast cancer (TNBC) or HR-positive HER2-negative MBC, with significant improvement in PFS and OS compared to standard chemotherapy. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.